Abstract Number: 1285 • ACR Convergence 2021
Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period
Background/Purpose: Disease activity is a major determinant of mortality whereas prolonged remission contributes to improving health outcomes in SLE patients (pts). Remission is thus a…Abstract Number: 1289 • ACR Convergence 2021
Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms
Background/Purpose: Lupus nephritis can occur as an isolated component of disease activity or be accompanied by diverse extrarenal symptoms that can adversely affect a patient’s…Abstract Number: 1482 • ACR Convergence 2021
LN Urinary Proteomics Reveals Common Biological Pathways Identified by Distinct Disease Measures
Background/Purpose: LN is a severe consequence of SLE and there is a huge unmet need for discovery of urine protein biomarkers that provide non-invasive surrogates…Abstract Number: 1568 • ACR Convergence 2021
AR882, a Potent and Selective Uricosuric Agent, Showed Effectiveness in Patients with Various Degrees of Renal Impairment
Background/Purpose: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout.…Abstract Number: 1757 • ACR Convergence 2021
Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: A Case Series
Background/Purpose: Belimumab is FDA approved for treatment of SLE and Lupus Nephritis. Patients with an eGFR < 30 ml/min/1.73m2 were excluded from clinical trials, thus…Abstract Number: 1937 • ACR Convergence 2021
IL-16 Is Linked to Lupus Nephritis Activity
Background/Purpose: There is a pressing need to identify novel therapeutic targets in lupus nephritis. Multiomic approaches hold great potential for discovery. We integrated urine proteomics…Abstract Number: 0327 • ACR Convergence 2021
Lipoprotein(a) in Systemic Lupus Erythematosus Is Associated with History of Proteinuria and Renal Insufficiency
Background/Purpose: Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease. Cardiovascular disease is one of the leading causes of death in patients…Abstract Number: 0419 • ACR Convergence 2021
Post-induction ANCA Titer Does Not Predict Mortality or Renal Outcomes: A Target Trial Emulation Study
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is associated with increased risk of end-stage renal disease (ESRD) and death. In most cases, circulating ANCA targeting…Abstract Number: 0423 • ACR Convergence 2021
Urine and Plasma Complement Ba Levels During Flares of Nephritis in Patients with ANCA-Associated Vasculitis
Background/Purpose: The alternative complement pathway has been implicated in the pathogenesis of ANCA-associated vasculitis (AAV), however it is not clear whether activation of complement occurs…Abstract Number: 0665 • ACR Convergence 2021
Pegloticase Treatment for Uncontrolled Gout in Kidney Transplanted Patients: Results of an On-going Multicenter, Open-Label, Efficacy and Safety Study
Background/Purpose: Gout in kidney transplant (KT) recipients can be severe and particularly challenging to manage. Pegloticase (pegylated recombinant uricase) rapidly metabolizes urate and is a…Abstract Number: 0875 • ACR Convergence 2021
Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity
Background/Purpose: Despite weight-based dosing, hydroxychloroquine (HCQ) efficacy varies between individuals. Our meta-analysis based on several studies found that low HCQ levels increased risk of lupus…Abstract Number: 1387 • ACR Convergence 2020
Should Systemic Sclerosis Patients with Low Bicarbonate Have Replacement to Prevent Renal Dysfunction?
Background/Purpose: Scleroderma renal crisis (SRC) is a well-characterized condition in patients with systemic sclerosis, but systemic sclerosis patients frequently develop chronic kidney disease (CKD) without…Abstract Number: 1425 • ACR Convergence 2020
Reduced Risk of Cardiovascular Diseases Events with Renal Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data System
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a common cause of glomerulonephritis and leads to end-stage renal disease (ESRD) in approximately 25% of patients. Both GPA…Abstract Number: 1512 • ACR Convergence 2020
Trajectory Analysis of Repeat Renal Biopsies Identified Previous Endocapillary Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Nephritis
Background/Purpose: . Pure membranous (class V) lupus nephritis is considered a less aggressive phenotype, but renal fibrosis and chronic kidney disease may develop. Whether this…Abstract Number: 1514 • ACR Convergence 2020
The Impact of Renal Transplantation on Cardiovascular Events Among Patients with End-State Kidney Disease Due to Lupus Nephritis: A Nationwide Cohort Study
Background/Purpose:A major complication of systemic lupus erythematosus (SLE) is the progression of lupus nephritis (LN) to end-stage kidney disease (ESKD). Both SLE and ESKD are…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- Next Page »